+65 3158 9940
1300 798 820
+64 9801 0299
Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the approval of ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), as a new first-line maintenance treatment option for adult patients in Australia and Singapore, who have been diagnosed with extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung cancer.
Singapore’s Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatment of patients with 4th line GIST QINLOCK significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in the INVICTUS Phase 3 Study1,2 Singapore, 8 May 2023: Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is
Singapore, 22 September 2021: SINGAPORE patients with an aggressive form of lung cancer (metastatic small cell cung cancer) can now access a new therapy that may improve outcomes. The drug ZEPZELCA (lurbinectedin) has been provisionally approved by Singapore’s Health Sciences Authority (HSA) “for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who
The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only. Timing Question 00:00:00 For recurrent desmoids or
The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only. Timing Question 00:01:15 After STRASS 1, the
The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only. [video_lightbox_youtube video_id=”c37cJBTkekA&rel=0″ width=”1522″ height=”775″ anchor=”Click Here To Watch The
The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only. [video_lightbox_youtube video_id=”Dg-Fv0UALMw&rel=0″ width=”1522″ height=”775″ anchor=”Click Here To Watch The
The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only. [video_lightbox_youtube video_id=”sr4nyJ0WVB0&rel=0″ width=”1522″ height=”775″ anchor=”Click Here To Watch The
The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only. [video_lightbox_youtube video_id=”ZHlheozCiuQ&rel=0″ width=”1522″ height=”775″ anchor=”Click Here To Watch The
Singapore, 14 September 2021: AUSTRALIAN patients with an aggressive form of lung cancer (metastatic Small Cell Lung Cancer) can now access a new therapy that may improve outcomes. The therapy, ZEPZELCA™ (lurbinectedin) has been approved by the Therapeutic Goods Administration (TGA) “for the treatment of patients with metastatic small cell lung cancer (SCLC) that has progressed